Peer-reviewed veterinary case report
How genomic tumor testing helps diagnose and treat dog cancers
By Chon, Esther et al.·Published in Journal of the American Veterinary Medical Association·2023·Translational Genomics Research Institute·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Genomic tumor analysis provides clinical guidance for the management of diagnostically challenging cancers in dogs.
- Species:
- dog
Plain-English summary
A group of 69 dogs with unclear cancer diagnoses underwent a special genomic test to help their veterinarians determine the best treatment options. This test provided clear diagnostic information for more than half of the cases and offered useful insights for many others, making it helpful in 86% of the situations. The genomic analysis helped guide treatment plans for dogs that were otherwise difficult to manage due to ambiguous cancer types. Overall, this study shows that genomic testing can be a valuable tool in treating canine cancers.
People also search for: dog cancer diagnosis test · genomic testing for dogs · unclear cancer treatment options for dogs
Abstract
OBJECTIVE: To evaluate the diagnostic, prognostic, and therapeutic utility of a cancer genomic diagnostic assay (SearchLight DNA; Vidium Animal Health) for diagnostically ambiguous cancer cases. ANIMALS: 69 privately owned dogs with ambiguous cancer diagnoses and for which the genomic assay was performed. PROCEDURES: Genomic assay reports generated between September 28, 2020, and July 31, 2022, for dogs with malignancy or suspected malignancy were reviewed to determine the assay's clinical utility defined as providing diagnostic clarity, prognostic information, and/or therapeutic options. RESULTS: Genomic analysis provided diagnostic clarity in 37 of 69 cases (54%; group 1) and therapeutic and/or prognostic information in 22 of the remaining 32 cases (69%; group 2) for which the diagnosis remained elusive. Overall, the genomic assay was clinically useful in 86% (59/69) of cases. CLINICAL RELEVANCE: To our knowledge, this was the first study to evaluate the multifaceted clinical utility of a single cancer genomic test in veterinary medicine. Study findings supported the use of tumor genomic testing for dogs with cancer, particularly those that are diagnostically ambiguous and therefore inherently challenging to manage. This evidence-driven genomic assay provided diagnostic guidance, prognostic support, and therapeutic options for most patients with an unclear cancer diagnosis that would otherwise have an unsubstantiated clinical plan. Furthermore, 38% (26/69) of samples were easily obtained aspirates. Sample factors (sample type, percentage of tumor cells, and number of mutations) did not influence diagnostic yield. Our study demonstrated the value of genomic testing for the management of canine cancer.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36862546/